Royal Bank of Canada
DSGN icon

Royal Bank of Canada’s Design Therapeutics DSGN Stock Holding History

Royal Bank of Canada’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Buy
11,366
+10,728
+1,682% +$109K ﹤0.01% 5015
2025
Q4 		$6K Buy
638
+193
+43% +$1.51K ﹤0.01% 6629
2025
Q3 		$4K Sell
445
-3,367
-88% -$16.9K ﹤0.01% 6742
2025
Q2 		$13K Buy
3,812
+1,006
+36% +$3.77K ﹤0.01% 6402
2025
Q1 		$11K Sell
2,806
-1,261
-31% -$6.02K ﹤0.01% 6121
2024
Q4 		$25K Sell
4,067
-856
-17% -$4.96K ﹤0.01% 6017
2024
Q3 		$27K Buy
4,923
+1,970
+67% +$9.27K ﹤0.01% 5992
2024
Q2 		$10K Buy
2,953
+2,219
+302% +$8.65K ﹤0.01% 6329
2024
Q1 		$3K Sell
734
-10,065
-93% -$26.9K ﹤0.01% 6582
2023
Q4 		$29K Buy
10,799
+5,298
+96% +$12.1K ﹤0.01% 6194
2023
Q3 		$13K Buy
5,501
+1,927
+54% +$8.99K ﹤0.01% 6331
2023
Q2 		$23K Buy
3,574
+1,508
+73% +$9.23K ﹤0.01% 6137
2023
Q1 		$12K Sell
2,066
-1,853
-47% -$13.9K ﹤0.01% 6229
2022
Q4 		$40K Buy
3,919
+3,505
+847% +$47.5K ﹤0.01% 6008
2022
Q3 		$7K Buy
414
+224
+118% +$4.46K ﹤0.01% 6583
2022
Q2 		$3K Sell
190
-1,444
-88% -$19.5K ﹤0.01% 6820
2022
Q1 		$26K Sell
1,634
-4,267
-72% -$65.4K ﹤0.01% 6461
2021
Q4 		$126K Buy
5,901
+4,311
+271% +$74K ﹤0.01% 5757
2021
Q3 		$23K Buy
1,590
+668
+72% +$11.1K ﹤0.01% 6627
2021
Q2 		$18K Buy
+922
New +$23.3K ﹤0.01% 6614

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royal Bank of Canada's DSGN Position: Q1 2026 in Review

Royal Bank of Canada increased its Design Therapeutics (DSGN) stake by 1,682% in Q1 2026, buying an estimated $109K and bringing the position to 11,366 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #5015.

Royal Bank of Canada first reported a position in DSGN in Q2 2021 and has held it in 20 quarters since. The position peaked at $126K in Q4 2021. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Royal Bank of Canada held 11,366 shares of Design Therapeutics worth $121K as of Q1 2026.
  • Royal Bank of Canada bought 10,728 Design Therapeutics shares in Q1 2026, an estimated $109K.
  • Design Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5015 holding.
  • Royal Bank of Canada first reported a position in Design Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Royal Bank of Canada's Design Therapeutics position peaked at $126K in Q4 2021.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.